Influenza, COVID-19, and Respiratory Syncytial Virus Vaccination Coverage Among Adults - United States, Fall 2024.

Autor: Kriss JL; Immunization Services Division, National Center for Immunization and Respiratory Diseases, CDC., Black CL; Immunization Services Division, National Center for Immunization and Respiratory Diseases, CDC., Razzaghi H; Immunization Services Division, National Center for Immunization and Respiratory Diseases, CDC., Meghani M; Immunization Services Division, National Center for Immunization and Respiratory Diseases, CDC., Tippins A; Immunization Services Division, National Center for Immunization and Respiratory Diseases, CDC., Santibanez TA; Immunization Services Division, National Center for Immunization and Respiratory Diseases, CDC., Stokley S; Immunization Services Division, National Center for Immunization and Respiratory Diseases, CDC., Chatham-Stephens K; Immunization Services Division, National Center for Immunization and Respiratory Diseases, CDC., Dowling NF; Immunization Services Division, National Center for Immunization and Respiratory Diseases, CDC., Peacock G; Immunization Services Division, National Center for Immunization and Respiratory Diseases, CDC., Singleton JA; Immunization Services Division, National Center for Immunization and Respiratory Diseases, CDC.
Jazyk: angličtina
Zdroj: MMWR. Morbidity and mortality weekly report [MMWR Morb Mortal Wkly Rep] 2024 Nov 21; Vol. 73 (46), pp. 1044-1051. Date of Electronic Publication: 2024 Nov 21.
DOI: 10.15585/mmwr.mm7346a1
Abstrakt: The Advisory Committee on Immunization Practices (ACIP) recommends annual influenza and COVID-19 vaccination for all persons aged ≥6 months, including adults aged ≥18 years. ACIP also recommends a single lifetime dose of respiratory syncytial virus (RSV) vaccine for adults aged ≥75 years and for those aged 60-74 years who are at increased risk for severe RSV disease. Data from the National Immunization Survey-Adult COVID Module, a random-digit-dialed cellular telephone survey of U.S. adults aged ≥18 years, are used to monitor influenza, COVID-19, and RSV vaccination coverage. By the week ending November 9, 2024, an estimated 34.7% of adults aged ≥18 years reported having received an influenza vaccine, and 17.9% reported having received a COVID-19 vaccine for the 2024-25 respiratory virus season; 39.7% of adults aged ≥75 years, and 31.6% of adults aged 60-74 years at increased risk for severe RSV, had ever received an RSV vaccine. Coverage varied by jurisdiction and demographic characteristics and was lowest among younger adults and those without health insurance. Although early season estimates indicate that many adults are unprotected from respiratory virus infections, many appeared open to vaccination: overall, approximately 35% and 41% of adults aged ≥18 years reported that they definitely or probably will receive or were unsure about receiving influenza and COVID-19 vaccines, respectively, and 40% of adults aged ≥75 years reported that they definitely or probably will receive or were unsure about receiving RSV vaccine. Health care providers and immunization programs still have time to expand outreach activities and promote vaccination to increase coverage in preparation for the height of the respiratory virus season. Using these data can help health care providers and immunization programs identify undervaccinated populations and understand vaccination patterns to guide planning, implementation, and evaluation of vaccination activities.
Competing Interests: All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.
Databáze: MEDLINE
Externí odkaz: